Session Recording - Personalising treatment in mHSPC
P3 PROSTATE CANCER FORUM 2026
Perspectives, Possibilities, Progress
This session focuses on personalising treatment in metastatic hormone-sensitive prostate cancer (mHSPC).
This on-demand hub gives you access to a selection of those sessions. The materials are intended to support day-to-day decision-making, encourage multidisciplinary discussion and sit alongside existing guidelines and local protocols.
The videos and PowerPoint presentations have been developed and funded by Bayer plc.
Session Recording - Personalising treatment in mHSPC:
The faculty review and discuss:
- ARANOTE and ARASENS data, including subgroup and post hoc analyses
- STOPCAP data
- Shared decision-making in prostate cancer care now and in the coming years
- Treatment options, treatment intensification and decision-making tools
- How virtual clinics may influence treatment pathways and follow-ups
Dr. Vincent Khoo, Consultant Clinical Oncologist, Royal Cornwall Hospitals NHS Trust.
Dr. Simon Hughes, Consultant Clinical Oncologist, Guy’s & St Thomas’ NHS Foundation Trust; Clinical Lead for Radiotherapy, The London Clinic, London.
Downloadable Slide Sets:
DOWNLOAD SLIDES →
Personalising Treatment in mHSPC - ARI Clinical Landscape
Presented by Prof. Vincent Khoo (Royal Marsden & St George's NHS Foundation Hospitals) - Summarising ARANOTE, ARASENS, and STOPCAP data as presented, with key points on treatment options, intensification strategies, and shared decision-making.
DOWNLOAD SLIDES →
Delivering Personalised Prostate Cancer Care via Shared Decision-Making - Practical Frameworks for mHSPC
Presented by Dr. Simon Hughes (Guy's & St. Thomas' NHS Foundation Trust) - Covering shared decision-making principles in mHSPC, with key points on treatment intensification, quality-of-life trade-offs, and aligning evidence with patient values.
Please refer to the NUBEQA summary of product characteristics before prescribing.
Abbreviations: ARI, androgen receptor inhibitor; mHSPC, metastatic hormone‑sensitive prostate cancer.
PP-NUB-GB-3080 | June 2026